PTC Therapeutics, Inc. (PTCT) Stock Forecast
PTCT analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.33 / 5 from 15 analysts
- Price target
- $97.94 average of analyst targets
- Upside to target
- +65.3% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $0.17
- 52-week range
- $59.24 – $89.55
PTCT analyst ratings
15 analystsNumber of analysts at each rating.
PTCT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PTCT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.30 | $0.24 | $0.36 | $0.19 | +59.7% | 3 |
| Current fiscal year (2026) | $1.52 | $1.23 | $1.82 | $7.62 | −80.1% | 3 |
| Next fiscal year (2027) | $2.37 | $1.82 | $3.04 | $1.52 | +56.3% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PTCT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $304.4M | $273.7M | $322.1M | +44.3% | 14 |
| Current fiscal year (2026) | $1.26B | $1.19B | $1.30B | −27.4% | 15 |
| Next fiscal year (2027) | $1.38B | $1.01B | $1.60B | +9.6% | 15 |
PTCT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PTCT revenue: reported and forecast
PTCT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.54 | $0.31 | $0.31 | $0.38 | $0.30 | −44.1% | 1 up · 1 down |
| Current fiscal year (2026) | $1.49 | $1.60 | $1.60 | $1.71 | $1.52 | +1.8% | 1 up · 1 down |
| Next fiscal year (2027) | $3.09 | $2.50 | $2.50 | $2.68 | $2.37 | −23.2% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PTCT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PTCT beat in 7 of 12.
What analysts expect from PTCT
15 analysts cover PTC Therapeutics; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $97.94, 65.3% above the latest close of $59.24. Analysts expect earnings of $1.52 per share for 2026, −80.1% from a year earlier. For 2027 the average estimate is $2.37 per share on revenue of $1.4 billion. PTC Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: PTCT income statement, PTCT key metrics, PTCT chart. See the PTCT stock overview for the latest quote and news.
PTCT forecast FAQ
What is PTC Therapeutics's price target?
The average analyst price target for PTC Therapeutics is $97.94, 65.3% above the latest close of $59.24.
Is PTC Therapeutics a buy, hold or sell?
Of 15 analysts covering PTC Therapeutics, 9 rate it a strong buy, 4 a buy, 1 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is PTC Therapeutics's EPS forecast?
Analysts forecast $1.52 per share for 2026 (range $1.23 to $1.82); for 2027 the estimate is $2.37.
What is PTC Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $1.3 billion, growth of −27.4%; for 2027 it is $1.4 billion.
When does PTC Therapeutics report earnings?
PTC Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes; the EPS estimate is $0.17.
Does PTC Therapeutics usually beat earnings estimates?
PTC Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.